Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders DSM-IV-TR4th edWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl15615000267
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• FleischhackerWWMcQuadeRDMarcusRNA double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophreniaBiol Psychiatry200965651051718986646
   PubMed Web of Science ®Google Scholar
• GurejeOMilesWKeksNOlanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New ZealandSchizophr Res2003612–330331412729882
   PubMed Web of Science ®Google Scholar
• TollefsonGDBeasleyCMJrTranPVOlanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trialAm J Psychiatry199715444574659090331
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• PerlickDARosenheckRAKaczynskiRBinghamSCollinsJAssociation of symptomatology and cognitive deficits to functional capacity in schizophreniaSchizophr Res2008991–319219917851042
   PubMed Web of Science ®Google Scholar
• KeefeRSYoungCARockSLOne-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophreniaSchizophr Res200681111516202565
   PubMed Web of Science ®Google Scholar
• PurdonSEJonesBDStipENeuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidolArch Gen Psychiatry200057324925810711911
   PubMed Web of Science ®Google Scholar
• GibsonPJDamlerRJacksonEAWilderTRamseyJLThe impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid populationValue Health200471223514720128
   PubMed Web of Science ®Google Scholar
• TunisSLFariesDENyhuisAWCost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trialValue Health200692778916626411
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• StroupTSMcEvoyJPSwartzMSTheNational Institute of Mental HealthClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentSchizophr Bull2003291153112908658
   PubMedGoogle Scholar
• StroupTSLiebermanJAMcEvoyJPEffectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticAm J Psychiatry2006163461162216585435
   PubMed Web of Science ®Google Scholar
• KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHOsuntokunOOFeldmanPDFactors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophreniaCompr Psychiatry
   Web of Science ®Google Scholar
• DavisSMStroupTSKochGGTime to all-cause treatment discontinuation as the primary outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia StudyStat Biopharm Res201132253265
   PubMed Web of Science ®Google Scholar
• BeasleyCMJrStaufferVLLiu-SeifertHAll-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisJ Clin Psychopharmacol200727325225817502771
   PubMed Web of Science ®Google Scholar
• BreierABergPHThakoreJHOlanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAm J Psychiatry2005162101879188716199834
   PubMed Web of Science ®Google Scholar
• KinonBJLiu-SeifertHAdamsDHCitromeLDifferential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophreniaJ Clin Psychopharmacol200626663263717110821
   PubMed Web of Science ®Google Scholar
• StromBLEngSMFaichGComparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)Am J Psychiatry2011168219320121041245
   PubMed Web of Science ®Google Scholar
• DeberdtWLipkovichIHeinlothANDouble-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorderTher Clin Risk Manag20084471372019209252
   PubMedGoogle Scholar
• DossenbachMPecenakJSzulcALong-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational studyJ Clin Psychiatry200869121901191519012820
   PubMed Web of Science ®Google Scholar
• GianfrancescoFRajagopalanKSajatovicMWangRHTreatment adherence among patients with schizophrenia treated with atypical and typical antipsychoticsPsychiatry Res20061442–317718917010448
   PubMed Web of Science ®Google Scholar
• HaroJMSuarezDNovickDThree-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies resultsEur Neuropsychopharmacol200717423524417137759
   PubMed Web of Science ®Google Scholar
• HattaKSatoKHamakawaHEffectiveness of second-generation antipsychotics with acute-phase schizophreniaSchizophr Res20091131495519553086
   PubMed Web of Science ®Google Scholar
• MullinsCDObeidatNACuffelBJNaradzayJLoebelADRisk of discontinuation of atypical antipsychotic agents in the treatment of schizophreniaSchizophr Res2008981–381517596914
   PubMed Web of Science ®Google Scholar
• NewcomerJWRatnerREErikssonJWA 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidoneJ Clin Psychiatry200970448749919358783
   PubMed Web of Science ®Google Scholar
• CooperDMoisanJGaudetMAbdousBGrégoireJPAmbulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophreniaCan J Psychiatry2005501490190816494259
   PubMed Web of Science ®Google Scholar
• KilziehNTodd-StenbergJAKennedyAWoodAETappAMTime to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient settingJ Clin Psychopharmacol2008281747718204345
   PubMed Web of Science ®Google Scholar
• RascatiKLJohnsrudMTCrismonMLLageMJBarberBLOlanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipientsPharmacoeconomics2003211068369712828491
   PubMed Web of Science ®Google Scholar
• RenXSQianSLeeAFHerzLMillerDRKazisLETreatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agentsJ Clin Pharm Ther2006311576516476121
   PubMed Web of Science ®Google Scholar
• StroupTSLiebermanJAMcEvoyJPEffectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE studyAm J Psychiatry2007164341542717329466
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• YamakawaYTerashimaYTanoueYA survey to examine patterns of prescribing atypical antipsychotic drugs for outpatients with schizophreniaJpn J Clin Psychopharmacol20101311631176 Japanese
   Google Scholar
• ZhaoZA retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophreniaManag Care Interface2002152758111875967
   PubMedGoogle Scholar
• KernRSGreenMFCornblattBAThe neurocognitive effects of aripiprazole: an open-label comparison with olanzapinePsychopharmacology (Berl)2006187331232016810506
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLandbloomRSwartzMSwansonJTime to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaBMC Psychiatry20066816504026
   PubMed Web of Science ®Google Scholar
• GerraGDi PettaGD’AmoreACombination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disordersClin Neuropharmacol200730312713517545747
   PubMed Web of Science ®Google Scholar
• IshigookaJInadaTMiuraSOlanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trialPsychiatry Clin Neurosci200155440341411442893
   PubMed Web of Science ®Google Scholar
• LiebermanJATollefsonGTohenMComparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidolAm J Psychiatry200316081396140412900300
   PubMed Web of Science ®Google Scholar
• MarshallTSMcCombsJSStafkey-MaileyDImpact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychoticsValue Health200912447348018798808
   PubMed Web of Science ®Google Scholar
• TiihonenJWahlbeckKLönnqvistJEffectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ2006333756122416825203
   PubMed Web of Science ®Google Scholar
• HodgsonRBelgamwarRAl-tawarahYMacKenzieGThe use of atypical antipsychotics in the treatment of schizophrenia in North StaffordshireHum Psychopharmacol200520214114715651052
   PubMed Web of Science ®Google Scholar
• JungSHKimWHChoiHJFactors affecting treatment discontinuation and treatment outcome in patients with schizophrenia in Korea: 10-year follow-up studyPsychiatry Investig2011812229
   Web of Science ®Google Scholar
• KreyenbuhlJSladeEPMedoffDRTime to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophreniaSchizophr Res20111311–312713221576008
   PubMed Web of Science ®Google Scholar
• GaebelWRiesbeckMvon WilmsdorffMDrug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST)Eur Neuropsychopharmacol201020531031620202800
   PubMed Web of Science ®Google Scholar
• TunisSLFariesDEStenslandMDHayDPKinonBJAn examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophreniaCurr Med Res Opin20072319710417257471
   PubMed Web of Science ®Google Scholar
• ChangCLTzengDSLungFWTreatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injectionPsychiatry Res20101801161920488552
   PubMed Web of Science ®Google Scholar
• ShinfukuNTanCHPharmacotherapy for schizophrenic inpatients in East Asia – changes and challengesInt Rev Psychiatry200820546046819012132
   PubMed Web of Science ®Google Scholar
• OshimaIMinoYInomataYHow many long-stay schizophrenia patients can be discharged in Japan?Psychiatry Clin Neurosci2007611717717239042
   PubMed Web of Science ®Google Scholar
• HaroJMKamathSAOchoaSThe Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand Suppl2003416162312755850
   PubMedGoogle Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• EuroQol – a new facility for the measurement of health-related quality of lifeThe EuroQol GroupHealth Policy199016319920810109801
   PubMed Web of Science ®Google Scholar
• KönigHHRoickCAngermeyerMCValidity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disordersEur Psychiatry200722317718717142014
   PubMed Web of Science ®Google Scholar
• NyhuisAWFariesDEAscher-SvanumHStaufferVLKinonBJPredictors of switching antipsychotic medications in the treatment of schizophreniaBMC Psychiatry2010107520920179
   PubMed Web of Science ®Google Scholar
• HaroJMNovickDSuarezDRocaMAntipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO studyJ Psychiatr Res200943326527318644606
   PubMed Web of Science ®Google Scholar
• KahnRFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
   PubMed Web of Science ®Google Scholar
• KinonBJLipkovichIEdwardsSBA 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptomsJ Clin Psychopharmacol200626215716216633144
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHWeidenPJPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAFariesDHeilerLKinonBTreatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotics during a one-year treatment for schizophreniaClin Schizophr Relat Psychoses200823226234
   Google Scholar
• GilmerTPDolderCRFolsomDPMastinWJesteDVAntipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004Psychiatr Serv20075871007101017602020
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMSuarezDPerezVDittmannRWHaddadPMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaPsychiatry Res20101762–310911320185182
   PubMed Web of Science ®Google Scholar
• ValensteinMGanoczyDMcCarthyJFMyra KimHLeeTABlowFCAntipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective reviewJ Clin Psychiatry200667101542155017107245
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• DunayevichEAscher-SvanumHZhaoFLonger time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorderJ Clin Psychiatry20076881163117117854239
   PubMed Web of Science ®Google Scholar